bisolol 5 mg tableta recubierta
grupo empresarial mendoza farmaceuticas s.a.c.- gemefar s.a.c. - droguerÍa - tableta recubierta - por tableta - - bisoprolol
paclitaxel 6 mgml
fresenius kabi oncology limited, planta baddi 2. - paclitaxel - solución concentrada para infusión iv - 6 mg/ml
atacand® 32 mg
astrazeneca ab.. - candesartán cilexetilo - tableta - 32 mg
fluconazol mk®
corporación bonima, s.a. de c.v. - fluconazol - cápsula - 150 mg
ketoconazol
empresa laboratorios medsol. unidad empresarial de base (ueb) "reinaldo gutiérrez", planta "reyval". - ketoconazol - tableta - 200 mg
saquinavir mesilato 500 mg tableta recubierta
seven pharma s.a.c. - droguerÍa - tableta recubierta - por tableta - - saquinavir
combicor 5mg comprimido recubierto
merck peruana s.a. - droguerÍa - comprimido recubierto - por comprimido - - bisoprolol
combicor 2.5mg comprimido recubierto
merck peruana s.a. - droguerÍa - comprimido recubierto - por comprimido - - bisoprolol
rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - agentes antineoplásicos - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
revelol xl 50, 47.5 mg tableta de liberacion prolongada
zennit farma s.a.c. - droguerÍa - tableta de liberacion prolongada - por tableta - - metoprolol